Prof. Dr. Meral Beksaç

Subcutaneous Daratumumab With Bortezomib, Lenalidomide, and Dexamethasone: HRQoL in TE NDMM Patients from PERSEUS

British Journal of Haematology, 2025

Quelle: ORCID

Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study

International Journal of Hematology, 2025

DOI 10.1007/s12185-025-03972-8 PMID 40234349 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma

Blood, 2025

DOI 10.1182/blood.2024027873 PMID 40279508 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: Europe PMC

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

HemaSphere, 2025

DOI 10.1002/hem3.70260 PMID 41306326 20 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

Parameters Associated With Renal Recovery and Survival in Myeloma Patients With Acute Renal Failure to Cast Nephropathy

American Journal of Hematology, 2025

DOI 10.1002/ajh.70104 PMID 41134013 6 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the chronic malignancies working party of the EBMT

Cytotherapy, 2025

DOI 10.1016/j.jcyt.2025.02.008 PMID 41128705 4 Zitationen (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

MM-1045: Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)02675-8 2 Zitationen (OpenAlex) Quelle: OpenAlex

Minimal residual disease (MRD) negativity (neg) in patients (pts) with relapsed or refractory multiple myeloma (RRMM) treated with belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide, bortezomib, and dexamethasone (PVd): Analysis from the DREAMM-8 trial.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.7515 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: OpenAlex

RETRACTED: Are Generic Imatinib Formulations Really as Effective as Originial Imatinib in Chronic Myeloid Leukemia: Real Life Data

Research Square, 2025

DOI 10.21203/rs.3.rs-2316364/v2 Frei zugänglicher VolltextQuelle: OpenAlex

Positron emission tomography with computed tomography (PET/CT) and minimal residual disease (MRD) for efficacy assessment in transplant-ineligible newly diagnosed myeloma (Ti NDMM) patients (pts): IMROZ analysis.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.7551 Frei zugänglicher VolltextQuelle: OpenAlex

Belantamab mafodotin + pomalidomide + dexamethasone (BPd) vs daratumumab + bortezomib + dexamethasone (DVd) in relapsed/refractory multiple myeloma: An indirect comparison using patient-level data.

Journal of Clinical Oncology, 2025

DOI 10.1200/jco.2025.43.16_suppl.7536 Frei zugänglicher VolltextQuelle: OpenAlex

POSTER: MM-1039 Characterization of Infections in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin-Based Regimens From the Randomized, Phase 3 DREAMM-7 and DREAMM-8 Trials

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)01314-x Quelle: OpenAlex

POSTER: MM-1045 Updated Results From the Phase 3 DREAMM-8 Study of Belantamab Mafodotin (Belamaf) Plus Pomalidomide and Dexamethasone (BPd) vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)01318-7 Quelle: OpenAlex

POSTER: MM-1486 Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)01372-2 Quelle: OpenAlex

MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)02630-8 Quelle: OpenAlex

MM-1486: Minimal Residual Disease Negativity in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone: Analysis From the DREAMM-8 Trial

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)02743-0 Quelle: OpenAlex

POSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)01280-7 Quelle: OpenAlex

Health-Related Quality of life (HRQoL) in Frail Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Isatuximab (Isa), Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRd) vs VRd Alone

Clinical Lymphoma Myeloma & Leukemia, 2025

DOI 10.1016/s2152-2650(25)03842-x Quelle: OpenAlex

Somatic variants and frequencies of familial myeloma germline predisposition genes among patients within the CoMMpass dataset

Expert Review of Hematology, 2025

DOI 10.1080/17474086.2025.2567299 PMID 40996854 Quelle: OpenAlex

A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant

Future Oncology, 2025

DOI 10.1080/14796694.2025.2560134 PMID 41058194 Frei zugänglicher VolltextQuelle: OpenAlex

Functional high-risk Relapsed/Refractory multiple myeloma (RRMM) outcomes with belantamab mafodotin (belamaf): Dreamm-7 and dreamm-8 subgroup analysis

Blood, 2025

DOI 10.1182/blood-2025-5820 Frei zugänglicher VolltextQuelle: OpenAlex

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis

Blood, 2025

DOI 10.1182/blood-2025-7567 Quelle: OpenAlex

Long-term outcomes of syngeneic transplantation in multiple myeloma: Valuable legacy or obsolete option? a study from the chronic malignancies working party of the EBMT

Blood, 2025

DOI 10.1182/blood-2025-6357 Frei zugänglicher VolltextQuelle: OpenAlex

Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022

Blood, 2025

DOI 10.1182/blood-2025-4583 Quelle: OpenAlex

Subcutaneous Daratumumab (Dara) plus Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients With Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival (OS) and Final Major Organ Deterioration Progression-Free Survival Results From the Phase 3 Andromeda

UCL Discovery (University College London), 2025

Quelle: OpenAlex

RESISTANCE MECHANISMS IN MULTIPLE MYELOMA IMMUNOTHERAPY

Turkiye Klinikleri eBooks, 2025

DOI 10.5336/978-625-395-657-8_p59 Quelle: OpenAlex

In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide

Current Research in Translational Medicine, 2024

DOI 10.1016/j.retram.2024.103444 PMID 38447268 1 Zitation (Europe PMC) Quelle: OpenAlex

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies

Blood Cancer Journal, 2024

DOI 10.1038/s41408-024-01149-w PMID 39609425 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

Blood Advances, 2024

DOI 10.1182/bloodadvances.2024013101 PMID 39024542 13 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Lenfoplazmasitik Lenfomada Yeni Nesil Dizileme Yöntemiyle Mutasyon İncelemesinin Tanı ve Tedavi Planında Yeri

LLM Dergi, 2024

DOI 10.5578/llm.202401127 Frei zugänglicher VolltextQuelle: ORCID

A Deeper Look Into Infections Among Myeloma Patients Treated With Daratumumab or Belantamab Mafodotin

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

A Germline Variant of BNIP1 Gene (rs28199) is Associated with Familial Multiple Myeloma

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma

Future Oncology, 2024

DOI 10.1080/14796694.2024.2394323 PMID 39287147 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Belantamab Mafodotin Plus Pomalidomide and Dexamethasone Vs Pomalidomide Plus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: A Subset Analysis in Patients Who Have Received 1 Prior Line of Therapy Including Lenalidomide

Blood, 2024

DOI 10.1182/blood-2024-199282 6 Zitationen (OpenAlex) Quelle: ORCID

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma

New England Journal of Medicine, 2024

DOI 10.1056/nejmoa2403407 PMID 38828951 157 Zitationen (Europe PMC) Quelle: ORCID

Belantamab Mafodotin, Pomalidomide, and Dexamethasone vs Pomalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Patient-Reported Outcomes from DREAMM-8

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparison

Leukemia and Lymphoma, 2024

DOI 10.1080/10428194.2023.2300051 PMID 38345269 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Characterization and Management of Ocular Events in Patients Treated With Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

Current Landscape of iPSC Haplobanks

Stem Cell Reviews and Reports, 2024

DOI 10.1007/s12015-024-10783-7 PMID 39276260 13 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Current barriers and recommendations on the diagnosis of transthyretin amyloid cardiomyopathy: a Delphi study

Frontiers in Cardiovascular Medicine, 2024

DOI 10.3389/fcvm.2024.1299261 PMID 38333414 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Daratumumab (DARA) plus bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial

Journal of Clinical Oncology, 2024

Quelle: ORCID

Daratumumab (DARA)/Bortezomib/Lenalidomide/Dexamethasone (D-VRd) With D-R Maintenance (Maint) in Transplant-eligible (TE) Newly Diagnosed Myeloma (NDMM): PERSEUS Cytogenetic Risk Analysis

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

Daratumumab maintenance in patients with myeloma

The Lancet Oncology, 2024

DOI 10.1016/s1470-2045(24)00341-3 PMID 38889736 1 Zitation (Europe PMC) Quelle: ORCID

Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

Daratumumab plus Bortezomib/ Lenalidomide/Dexamethasone in (D-VRd) Transplant-Eligible (TE) Patients With Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

Daratumumab plus Bortezomib/Lenalidomide/ Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study

Clinical Lymphoma Myeloma and Leukemia, 2024

Quelle: ORCID

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2024

DOI 10.1056/nejmoa2312054 PMID 38084760 482 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis

Journal of Clinical Oncology, 2024

Quelle: ORCID

In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT

Bone Marrow Transplantation, 2024

DOI 10.1038/s41409-023-02160-8 PMID 38297040 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

Inhibition of O6-methylguanine-DNA-methyltransferase (MGMT) by lomeguatrib reduces multiple myeloma cell viability and impairs DNA repair in MGMT-proficient cells

Chemical Biology and Drug Design, 2024

DOI 10.1111/cbdd.14465 1 Zitation (OpenAlex) Frei zugänglicher VolltextQuelle: ORCID